$141 Million is the total value of TRV GP, LLC's 5 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $79,231,000 | -31.5% | 3,981,437 | 0.0% | 56.15% | +7.4% | |
| CTMX | Sell | CYTOMX THERAPEUTICS, INC. | $29,029,000 | -58.6% | 1,020,348 | -69.3% | 20.57% | -35.1% |
| KALA | KALA PHARMACEUTICALS INC. | $26,190,000 | -14.4% | 1,654,425 | 0.0% | 18.56% | +34.3% | |
| EBIO | ELEVEN BIOTHERAPEUTICS, INC. | $5,084,000 | +29.6% | 4,841,591 | 0.0% | 3.60% | +103.3% | |
| ZFGN | ZAFGEN, INC. | $1,567,000 | +61.2% | 210,371 | 0.0% | 1.11% | +153.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Mark Levin #1
- Kevin P. Starr #2
- Robert I. Tepper #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-04-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SESEN BIO, INC. | 13 | Q4 2020 | 100.0% |
| RHYTHM PHARMACEUTICALS, INC. | 8 | Q3 2019 | 80.0% |
| CONSTELLATION PHARMACEUTICALS INC. | 8 | Q2 2020 | 96.6% |
| ZAFGEN, INC. | 7 | Q2 2019 | 2.0% |
| KALA PHARMACEUTICALS INC. | 3 | Q2 2018 | 18.6% |
| SESEN BIO, INC. | 2 | Q2 2021 | 100.0% |
| CYTOMX THERAPEUTICS, INC. | 2 | Q1 2018 | 31.7% |
| 0 | 1 | Q3 2021 | 0.0% |
View TRV GP, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-05 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-06 |
| 13F-HR | 2020-08-07 |
| 13F-HR | 2020-05-11 |
| 13F-HR | 2020-02-05 |
| 13F-HR | 2019-11-04 |
| 13F-HR | 2019-08-06 |
View TRV GP, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.